Accord And Sandoz Lead Victories At GGB Awards 2022
Firms Win Multiple Awards Alongside Other Companies Recognized In Frankfurt
Accord and Sandoz were the big winners at the Global Generics & Biosimilars Awards 2022 in Frankfurt, with other firms recognized including Beximco, Centrient, Dr Reddy’s, Eurofarma, Samsung Bioepis, Shanghai Henlius Biotech and Stada, as well as the US Biosimilars Forum.
Accord Healthcare and Sandoz have emerged as the major winners at the Global Generics & Biosimilars Awards 2022, with Accord picking up four trophies and Sandoz being crowned the winner in two categories and receiving a commendation in a third, alongside multiple other prizes handed out in Frankfurt, Germany, on 2 November.
As well as being crowned as global company of the year, Accord – described by our judges describing as “a key provider of generic medicines and biopharmaceuticals across many countries” – also picked up the award for biosimilar initiative of the year linked to Zercepac (trastuzumab), the first Chinese-origin mAb ever launched in Europe.
The company also won the awards for value-added medicine initiative of the year for the Sixmo (buprenorphine) implant (Also see "Accord Aims At Addiction With Buprenorphine Implant Deal" - Generics Bulletin, 14 Sep, 2020.); and regulatory achievement of the year for the firm’s Camcevi (leuprorelin) treatment. (Also see "Accord Sees Two Hybrids Endorsed By EU’s CHMP" - Generics Bulletin, 25 Mar, 2022.)
Meanwhile, Sandoz won the award for company of the year in the EMEA region as CEO Richard Saynor also picked up the award for leader of the year. The firm’s highly commended recognition came in the corporate social responsibility initiative of the year category – for its Act4Biosimilars campaign (Also see "Sandoz Launches Global Biosimilars Initiative" - Generics Bulletin, 31 May, 2022.) – with the CSR category being won by Eurofarma for its Eurofarma Nursing Education Center project.
In the other regional company of the year categories, Samsung Bioepis was named the winner in the APAC region while Dr Reddy’s was recognized in the Americas region in part for its cancer care companion solution Alivius, piloted in Colombia.
Beximco Pharmaceuticals won the award for acquisition of the year after acquiring a majority shareholding of Sanofi Bangladesh in late 2021 (Also see "Beximco Completes Acquisition Of Sanofi Bangladesh" - Generics Bulletin, 5 Oct, 2021.), while Shanghai Henlius Biotech triumphed in the business development category after closing multiple out-licensing deals for its biosimilars. (Also see "Organon Strikes $100m+ Global Deal For Henlius’ Denosumab And Pertuzumab" - Generics Bulletin, 13 Jun, 2022.)
Centrient was named active pharmaceutical ingredient supplier of the year after achieving 100% compliance with the stringent discharge targets set by the AMR Industry Alliance (Also see "As Antibiotics Recover, Centrient Maintains Focus On Sustainability" - Generics Bulletin, 25 Oct, 2022.); and Stada took home the award for intellectual property strategy of the year was Stada in connection with its bortezomib.
Finally, the US Biosimilars Forum was named industry partner of the year, with our judges offering “kudos for the excellent work performed” by the association to “communicate the benefits of biosimilars” and “tackle the many hurdles in the US biosimilars market.” (Also see "Reed Sets Out Priorities For US Biosimilars Forum" - Generics Bulletin, 16 Feb, 2022.)
“Congratulations to all of tonight’s winners and all those that were shortlisted for the awards,” said David Wallace, executive editor of Generics Bulletin. “It was truly great to return to Frankfurt and celebrate what a fantastic year we have had for generics and biosimilars. As ever, the standard of entries was extremely high, which gave the judges a very difficult task in awarding the winners.”
“I would like to also extend my thanks to our sponsors – our drinks reception sponsor Aurobindo, our social media sponsor Insud Pharma, our category sponsors Pharmacloud, Pharmawise, SanaClis, Stada, and West Pharma, and especially our headline sponsor IQVIA – as well as to our expert judges. We look forward to celebrating with you all again next year.”
Full details of this year’s winners are available here.
To enquire about sponsorship opportunities for the Global Generics & Biosimilars Awards 2023, please e-mail email@example.com
And to register interest in attending the Global Generics & Biosimilars Awards 2023, to receive the latest updates and for any further details, please e-mail firstname.lastname@example.org